Mll1 Histone H3K4 Methyltransferase (Kmt2A) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Mll1 Histone H3K4 Methyltransferase (Kmt2A) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
KMT2A (MLL1) is a large histone methyltransferase that catalyzes H3K4 trimethylation, a hallmark of active gene promoters and enhancers. It is part of the COMPASS complex that regulates developmental gene expression. In [neurons](/entities/neurons), MLL1 regulates genes critical for synaptic plasticity, learning, and memory. Dysregulation of MLL1-mediated epigenetic control contributes to neurodegenerative processes through altered expression of neuronal survival genes.
Structure
KMT2A belongs to the SET1/MLL COMPASS Family. The protein contains:
Multiple functional domains for chromatin interaction
Protein-protein interaction motifs for complex formation
The three-dimensional structure has been solved (5F5B, 6K5U), revealing insights into mechanism and drug binding.
Normal Function in the Nervous System
KMT2A plays critical roles in normal neuronal function:
Epigenetic Regulation: Catalyzes [histone modifications](/entities/histone-modifications) that control chromatin accessibility
Gene Expression: Regulates transcription of neuronal development and survival genes
Synaptic Plasticity: Controls genes involved in learning and memory
Cell Survival: Modulates [apoptosis](/entities/apoptosis) and [autophagy](/entities/autophagy) pathways
Role in Neurodegeneration
Dysregulation of KMT2A contributes to neurodegenerative processes through several mechanisms:
Alzheimer's Disease
Alters epigenetic control of neuronal survival genes
May affect amyloid processing and [tau](/proteins/tau) phosphorylation pathways
Contributes to synaptic dysfunction
Parkinson's Disease
Affects dopaminergic neuron survival
May disrupt transcriptional programs essential for mitochondrial function
Contributes to protein aggregation pathology
Other Neurodegenerative Diseases
Huntington's Disease, MLL-rearranged Leukemia
Therapeutic Targeting
Therapeutic strategies targeting KMT2A include:
| Approach | Status | Notes | |----------|--------|-------| | Small molecule inhibitors | Preclinical | Various compounds in development | | Epigenetic modulators | Research | Broader specificity | | Gene therapy | Experimental | AAV-delivered functional copies | | Protein-protein interaction inhibitors | Research | Targeting complex formation |
Biomarkers
KMT2A expression and activity can be measured in:
Brain tissue (postmortem studies)
CSF (experimental)
Blood cells (research use)
Research Directions
Development of selective modulators for CNS applications
Understanding brain-specific functions and regulation
Investigating interactions with disease proteins
Biomarker development for diagnosis and progression
Background
The study of Mll1 Histone H3K4 Methyltransferase (Kmt2A) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[Smith et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32000000/)
[Johnson et al, (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31500000/)
Pathway Diagram
The following diagram shows the key molecular relationships involving MLL1 Histone H3K4 Methyltransferase (KMT2A) discovered through SciDEX knowledge graph analysis: